Yee Weng Wong, M.B.B.S., M.H.S.

  1. Cardiologist
  2. Echocardiographer
  3. Transplant Cardiologist
  1. Nouhravesh N, Garg J, Rockhold FW, De Pasquale CG, O'Meara E, Lewis GD, Butler J, Harrington J, Ezekowitz JA, Ponikowski P, Troughton RW, Wong YW, Blackman N, Numan S, Adamczyk R, Hernandez AF, Mentz RJ. Characterization of serum phosphate levels over time with intravenous ferric carboxymaltose versus placebo as treatment for heart failure with reduced ejection fraction and iron deficiency: An exploratory prospective substudy from HEART-FID. Eur J Heart Fail. 2024 Jun 19 Epub 2024 June 19
    View PubMed
  2. Harrington J, Mentz RJ, Rockhold FW, Garg J, Butler J, De Pasquale CG, Ezekowitz JA, Lewis GD, O'Meara E, Ponikowski P, Troughton RW, Wong YW, Adamczyk R, Storie T, Blackman N, Hernandez AF. Hierarchical End Points in Prior Heart Failure Trials and the HEART-FID Trial. Circ Heart Fail. 2024 Feb; 17 (2):e010676 Epub 2024 Jan 22
    View PubMed
  3. Wong YW, Haqqani H, Molenaar P. Roles of beta-adrenoceptor Subtypes and Therapeutics in Human Cardiovascular Disease: Heart Failure, Tachyarrhythmias and Other Cardiovascular Disorders. Handb Exp Pharmacol. 2024; 285:247-295
    View PubMed
  4. Harrington J, Mentz RJ, Rockhold FW, Garg J, Butler J, De Pasquale CG, Ezekowitz JA, Lewis GD, O'Meara E, Ponikowski P, Troughton RW, Wong YW, Adamczyk R, Blackman N, Hernandez AF. Baseline characteristics of patients in the randomized study to investigate the efficacy and safety of ferric carboxymaltose as treatment for heart failure with iron deficiency: HEART-FID trial. Am Heart J. 2023 Dec; 266:25-31 Epub 2023 Aug 19
    View PubMed
  5. Mentz RJ, Garg J, Rockhold FW, Butler J, De Pasquale CG, Ezekowitz JA, Lewis GD, O'Meara E, Ponikowski P, Troughton RW, Wong YW, She L, Harrington J, Adamczyk R, Blackman N, Hernandez AF, HEART-FID Investigators. Ferric Carboxymaltose in Heart Failure with Iron Deficiency. N Engl J Med. 2023 Sep 14; 389 (11):975-986 Epub 2023 Aug 26
    View PubMed
  6. Khoo JK, Trewin BP, Adji A, Wong YW, Hungerford S. ST elevation myocardial infarction complicated by cardiogenic shock: Systematic review of survival predictors American Journal of Medicine Open. 2023.
  7. Bois JP, Ayoub C, Geske JB, Wong YW, Abbasi MA, Foley TA, Mulvagh SL, Scott CG, Ommen SR, Pellikka PA. Ultrasound Enhancing Agents with Transthoracic Echocardiography for Maximal Wall Thickness in Hypertrophic Cardiomyopathy. Mayo Clin Proc Innov Qual Outcomes. 2023 Aug; 7(4):309-319. Epub 2023 Jul 19.
    View PubMed
  8. Chamberlain R, Edwards NFA, Doyle SN, Wong YW, Scalia GM, Sabapathy S, Chan J. Prognostic Value of Left and right ventricular deformation strain analysis on Acute Cellular rejection in Heart Transplant recipients: A 6-year outcome study. Int J Cardiovasc Imaging. 2022 Nov; 38 (11):2271-2281 Epub 2022 Aug 08
    View PubMed
  9. Gan J, Rheault H, Wong YW. Who 'nose', is it the angiotensin receptor neprilysin inhibitor?: a case series of persistent nasal pruritus in heart failure patients receiving sacubitril/valsartan. Eur Heart J Case Rep. 2021 Dec; 5(12):ytab506. Epub 2021 Dec 11.
    View PubMed
  10. Mentz RJ, Ambrosy AP, Ezekowitz JA, Lewis GD, Butler J, Wong YW, De Pasquale CG, Troughton RW, O'Meara E, Rockhold FW, Garg J, Samsky MD, Leloudis D, Dugan M, Mundy LM, Hernandez AF, HEART-FID Trial Investigators. Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design. Circ Heart Fail. 2021 May; 14 (5):e008100 Epub 2021 May 18
    View PubMed
  11. Dashwood A, Cheesman E, Wong YW, Haqqani H, Beard N, Hay K, Spratt M, Chan W, Molenaar P. Effects of omecamtiv mecarbil on failing human ventricular trabeculae and interaction with (-)-noradrenaline. Pharmacol Res Perspect. 2021 May; 9(3):e00760.
    View PubMed
  12. Dashwood A, Vale C, Laher S, Chui F, Hay K, Wong YW. Hypophosphatemia Is Common After Intravenous Ferric Carboxymaltose Infusion Among Patients With Symptomatic Heart Failure With Reduced Ejection Fraction. J Clin Pharmacol. 2021 Apr; 61 (4):515-521 Epub 2020 Oct 13
    View PubMed
  13. Dashwood A, Beard N, Wong YW, Haqqani H, Cheesman E, Molenaar P. Correction to "Understanding How Phosphorylation and Redox Modifications Regulate Cardiac Ryanodine Receptor Type 2 Activity to Produce an Arrhythmogenic Phenotype in Advanced Heart Failure". ACS Pharmacol Transl Sci. 2020 Dec 11; 3 (6):1422 Epub 2020 Oct 19
    View PubMed
  14. Dashwood A, Vale C, Laher S, Chui F, Rheault H, Gan J, Wong YW. Impact of Patient and Model of Care Factors on Titration and Tolerability of Sacubitril/Valsartan: An Early Australian Real-World Experience. Heart Lung Circ. 2020 Nov; 29 (11):1688-1695 Epub 2020 Apr 09
    View PubMed
  15. Laher S, Wong YW, Platts D, Prabhu A, Thomson B, Hamilton-Craig C, Godbolt D, Cheesman E, Dashwood A. A Rare Case of Severe Nontropical Isolated Right Ventricular Endomyocardial Fibrosis. JACC Case Rep. 2020 Nov; 2 (13):2078-2084 Epub 2020 Nov 18
    View PubMed
  16. Dashwood A, Cheesman E, Beard N, Haqqani H, Wong YW, Molenaar P. Understanding How Phosphorylation and Redox Modifications Regulate Cardiac Ryanodine Receptor Type 2 Activity to Produce an Arrhythmogenic Phenotype in Advanced Heart Failure. ACS Pharmacol Transl Sci. 2020 Aug 14; 3 (4):563-582 Epub 2020 June 01
    View PubMed
  17. Krishnan A, Markham R, Savage M, Wong YW, Walters D. Right Heart Catheterisation: How To Do It. Heart Lung Circ. 2019 Apr; 28 (4):e71-e78 Epub 2018 Sept 06
    View PubMed
  18. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Ohman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF, EXSCEL Study Group. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017 Sep 28; 377 (13):1228-1239 Epub 2017 Sept 14
    View PubMed
  19. AbouEzzeddine OF, Wong YW, Mentz RJ, Raza SS, Nativi-Nicolau J, Kociol RD, McNulty SE, Anstrom KJ, Hernandez AF, Redfield MM, NHLBI Heart Failure Clinical Research Network. Evaluation of Novel Metrics of Symptom Relief in Acute Heart Failure: The Worst Symptom Score. J Card Fail. 2016 Nov; 22 (11):853-858 Epub 2015 Dec 21
    View PubMed
  20. Wong YW, Mentz RJ, Felker GM, Ezekowitz J, Pieper K, Heizer G, Hasselblad V, Metra M, O'Connor CM, Armstrong PW, Starling RC, Hernandez AF. Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials. Eur J Heart Fail. 2016 Jun; 18 (6):684-92 Epub 2016 Jan 27
    View PubMed
  21. Wong YW, Fonarow GC, Mi X, Peacock WF 4th, Mills RM, Curtis LH, Qualls LG, Hernandez AF. Early intravenous heart failure therapy and outcomes among older patients hospitalized for acute decompensated heart failure: findings from the Acute Decompensated Heart Failure Registry Emergency Module (ADHERE-EM). Am Heart J. 2013 Aug; 166 (2):349-56 Epub 2013 July 01
    View PubMed
  22. Wong YW, Thomas L, Sun JL, McMurray JJ, Krum H, Hernandez AF, Rutten GE, Leiter LA, Standl E, Haffner SM, Mazzone T, Martinez FA, Tognoni G, Giles T, Califf RM. Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study. Circ Heart Fail. 2013 Mar; 6 (2):203-10 Epub 2013 Feb 06
    View PubMed
  23. Wong YW, Prakash R, Chew DP. Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents. Curr Opin Cardiol. 2010 Jul; 25 (4):305-11
    View PubMed
  24. Kennedy JA, Beck-Oldach K, McFadden-Lewis K, Murphy GA, Wong YW, Zhang Y, Horowitz JD. Effect of the anti-anginal agent, perhexiline, on neutrophil, valvular and vascular superoxide formation. Eur J Pharmacol. 2006 Feb 15; 531 (1-3):13-9 Epub 2006 Jan 17
    View PubMed